Zentalis Pharmaceuticals, Inc.
Zentalis develops azenosertib, a WEE1 inhibitor in clinical development for ovarian cancer and multiple tumor types.
20-FSep 30Latest SEC filing
Aug 14Latest story
Sign inSign inZentalis develops azenosertib, a WEE1 inhibitor in clinical development for ovarian cancer and multiple tumor types.